Reinforced vascular protheses

Patent metadata

Field	Value
Publication number	US-9498559-B2
Application number	US-201414566209-A
Country	US
Kind code	B2
Filing date	Dec 10, 2014
Priority date	Oct 8, 2012
Publication date	Nov 22, 2016
Grant date	Nov 22, 2016

Abstract

Vascular grafts for treating, reconstructing and replacing damaged or diseased cardiovascular vessels that are formed from decellularized extracellular matrix (ECM). The vascular grafts include outer or outer and inner coatings that provide structural reinforcement.

First claim

What is claimed is:

1. A vascular graft for treating damaged or diseased tissue in cardiovascular vessels, comprising:
a biodegradable and remodelable tubular member comprising an extracellular matrix (ECM) composition comprising acellular ECM from a mammalian tissue source and an ECM-mimicking biomaterial comprising poly(glycerol sebacate) (PGS),
said tubular member comprising an outer surface and a lumen that extends therethrough, said lumen defining a tubular member inner surface,
said tubular member further comprising at least one biodegradable coating disposed on said tubular member outer surface,
said tubular member being configured to induce modulated healing when disposed proximate damaged cardiovascular tissue, said modulated healing comprising modulation of inflammation of said damaged tissue, and induced host tissue proliferation, bioremodeling of said damaged tissue, and regeneration of new cardiovascular tissue and tissue structures with site specific structural and functional properties.

2. The vascular graft of claim 1 , wherein said mammalian tissue source is selected from the group consisting of small intestine submucosa (SIS), urinary bladder submucosa (UBS), urinary basement membrane (UBM), liver basement membrane (LBM), stomach submucosa (SS) and mesothelial tissue.

3. The vascular graft of claim 2 , wherein said ECM composition further comprises a first supplemental biologically active agent.

4. The vascular graft of claim 3 , wherein said first supplemental biologically active agent comprises a growth factor selected from the group consisting of transforming growth factor-alpha (TGF-α), transforming growth factor-beta (TGF-β), fibroblast growth factor-2 (FGF-2), and vascular epithelial growth factor (VEGF).

5. The vascular graft of claim 4 , wherein said growth factor is encapsulated in a first osmotic fluctuation inducing composition.

6. The vascular graft of claim 1 , wherein said acellular ECM material comprises adolescent acellular ECM.

7. The vascular graft of claim 1 , wherein said ECM composition further comprises at least a first pharmacological agent.

8. The vascular graft of claim 7 , wherein said first pharmacological agent comprises an agent selected from the group consisting of an antibiotic, anti-viral agent, analgesic, anti-inflammatory, anti-neoplastic, anti-spasmodic, and anticoagulant and antithrombic agent.

9. The vascular graft of claim 7 , wherein said first pharmacological agent comprises a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

10. The vascular graft of claim 9 , wherein said statin is encapsulated in a second osmotic fluctuation inducing composition.

11. The vascular graft of claim 10 , wherein said tubular member comprises a multi-stage delivery vehicle.

12. The vascular graft of claim 1 , wherein said biodegradable coating comprises a first polymeric composition coating comprising a first biodegradable polymeric material selected from the group consisting of poly(ε-caprolactone-co-glycolide)(PCL), polyhydroxy-alkonate (PHA) polylactide (PLLA), polyglycolide (PLGA) and copolymers thereof, and polyanhydride.

13. The vascular graft of claim 1 , wherein said biodegradable coating further comprises a second pharmacological agent.

14. The vascular graft of claim 13 , wherein said second pharmacological agent comprises an agent selected from the group consisting of an antibiotic, anti-viral agent, analgesic, anti-inflammatory, anti-neoplastic, anti-spasmodic, and anticoagulant and antithrombic agent.

15. The vascular graft of claim 13 , wherein said second pharmacological agent comprises a statin selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin and simvastatin.

16. The vascular graft of claim 1 , wherein said tubular member further comprises a reinforcing structure, said reinforcing structure being disposed proximate said tubular member outer surface.

17. The vascular graft of claim 16 , wherein said reinforcing structure comprises a woven structure.

18. The vascular graft of claim 16 , wherein said reinforcing structure comprises a second polymeric composition coating comprising a second biodegradable polymeric material selected from the group consisting of PCL, PHA, PLLA, PLGA and copolymers thereof, and polyanhydride.

19. The vascular graft of claim 16 , wherein said reinforcing structure comprises PGS.

20. The vascular graft of claim 1 , wherein said acellular ECM comprises ECM selected from the group consisting of subcutaneous extracellular matrix, large intestine extracellular matrix, placental extracellular matrix, omentum extracellular matrix, heart extracellular matrix and lung extracellular matrix.

Assignees

• Cormatrix Cardiovascular Inc

Inventors

• Matheny Robert G

Classifications

• A61F2210/0014

  using shape memory or superelastic materials, e.g. nitinol · CPC title

• A61L27/54

  Biologically active materials, e.g. therapeutic substances {(A61L27/227 takes precedence)} · CPC title

• A61L27/3633 Primary

  Extracellular matrix [ECM] · CPC title

• A61L2300/216

  with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups · CPC title

• A61F2220/0075

  sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable · CPC title